Cargando…
Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China
BACKGROUND: Hepatitis B surface antigen clearance or seroconversion is rarely achieved for patients using nucleoside analogs or pegylated interferon alpha monotherapy approaches. Several recent studies have confirmed the benefit of a combination of these two approaches for selected chronic hepatitis...
Autores principales: | Li, Runqin, Lin, Xiao, Wang, Jing-Yue, Wang, Xiaomo, Lu, Junfeng, Liu, Yali, Cao, Zhenhuan, Ren, Shan, Ma, Lina, Jin, Yi, Zheng, Sujun, Hu, Zhongjie, Wang, Li, Chen, Xinyue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506536/ https://www.ncbi.nlm.nih.gov/pubmed/34733917 http://dx.doi.org/10.21037/atm-21-1666 |
Ejemplares similares
-
Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
por: Zhao, Jing, et al.
Publicado: (2023) -
HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014) -
The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007) -
Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection
por: Song, Aixin, et al.
Publicado: (2022) -
Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)